Unknown

Dataset Information

0

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.


ABSTRACT: The management of HER2 positive breast cancer has been transformed by the development of targeted therapies. Dual blockade with the monoclonal antibodies, trastuzumab and pertuzumab, added to first-line taxane chemotherapy and second-line therapy with the antibody-drug conjugate, T-DM1, are internationally agreed standards of care for advanced HER2 positive breast cancer, where available. However, until recently, options for patients for third-line therapy and beyond were of modest efficacy or limited by toxicity. In 2019, the results of trials of two exciting new agents for this space were presented. A third-generation HER2 tyrosine kinase inhibitor, tucatinib, combines the efficacy of the second-generation drug, neratinib, with a more manageable toxicity profile and has become a new standard of care after T-DM1, in combination with capecitabine and trastuzumab. The antibody-drug conjugate, trastuzumab deruxtecan, demonstrated remarkable efficacy in heavily pre-treated patients and received accelerated approval in the United States, whilst confirmatory Phase 3 trials are completed. This review will discuss the available data for the post-T-DM1 setting, focusing on tyrosine kinase inhibitors including tucatinib.

SUBMITTER: Ulrich L 

PROVIDER: S-EPMC8164963 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8103530 | biostudies-literature
| S-EPMC6143009 | biostudies-literature
| S-EPMC4180403 | biostudies-literature
| S-EPMC7817741 | biostudies-literature
| S-EPMC10578436 | biostudies-literature
| S-EPMC7812178 | biostudies-literature
| S-EPMC5674043 | biostudies-literature
| S-EPMC9012688 | biostudies-literature
| S-EPMC10993071 | biostudies-literature
| S-EPMC5125250 | biostudies-literature